Skip to main content
BEIJING CENTERGATE TECHNOLOGIES (HOLDING) CO., LTD logo

BEIJING CENTERGATE TECHNOLOGIES (HOLDING) CO., LTD — Investor Relations & Filings

Ticker · 000931 ISIN · CNE000001030 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,999 across all filing types
Latest filing 2024-09-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000931

About BEIJING CENTERGATE TECHNOLOGIES (HOLDING) CO., LTD

https://www.centek.com.cn

Beijing Centergate Technologies (Holding) Co., Ltd. focuses on the research, development, production, and distribution of medical and healthcare products. The company’s core operations involve the manufacturing of chemical pharmaceuticals, traditional Chinese medicines, and health supplements. Its product portfolio addresses various therapeutic areas, including cardiovascular health, digestive system treatments, and anti-infective therapies. Additionally, the company provides healthcare services and develops medical devices. Through its specialized subsidiaries, it maintains integrated research and manufacturing capabilities aimed at providing clinical solutions and health management products. The organization emphasizes technological advancement and quality control across its supply chain to meet diverse patient needs and healthcare standards.

Recent filings

Filing Released Lang Actions
关于下属公司北京华素盐酸纳曲酮片一致性评价申报收到国家药品监督管理局《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Zhongguancun Technology Development (Holding) Co., Ltd. regarding the receipt of an acceptance notice from the National Medical Products Administration for a consistency evaluation application of a pharmaceutical product. It is a regulatory announcement about the acceptance of a drug evaluation application, not a financial report or detailed financial data. The document is short (1133 characters) and serves as a formal notification to investors about regulatory progress and potential impact on the company. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-13 Chinese
重大诉讼进展公告
Legal Proceedings Report Classification · 100% confidence The document is titled as a "重大诉讼进展公告" which translates to "Major Litigation Progress Announcement." It details the status of a legal case involving the company as plaintiff, including the court's first-instance judgment, the amount involved, and the potential impact on the company's profits. It also references a previous announcement and states that the company will continue to disclose information as required by law. There are no financial statements or management discussion of financial results, nor is this a full annual or interim report. The content is focused on legal proceedings and updates about a lawsuit. Therefore, this document fits the category of Legal Proceedings Report (LTR). The document length is short and it is not merely an announcement of a report but contains substantive information about the litigation progress and court judgment.
2024-09-12 Chinese
关于与山东百诺医药股份有限公司签订战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation framework agreement between Beijing Zhongguancun Technology Development (Holding) Co., Ltd. and Shandong Bainuo Pharmaceutical Co., Ltd. It details the parties involved, the nature of the cooperation, rights and obligations, and risk disclosures. There is no financial data, quarterly or annual report content, or regulatory certification. The document is a formal announcement of a business cooperation agreement, not a financial report or management change notice. It fits best under a general regulatory announcement category for disclosures that do not fit other specific categories.
2024-09-09 Chinese
关于与海徕科（北京）生物技术有限公司签订战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Zhongguancun Technology Development (Holdings) Co., Ltd. about signing a strategic cooperation framework agreement with Hailike (Beijing) Biotechnology Co., Ltd. It details the parties involved, the nature of the cooperation, the terms of the agreement, and the potential impact on the company. The document is structured as a formal announcement with no financial statements or detailed financial analysis. It does not contain quarterly or annual financial results, audit opinions, or management discussion and analysis. The document is not a report but an announcement of a corporate event related to strategic cooperation. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-09 Chinese
关于控股股东一致行动人部分股份被轮候冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the partial judicial freezing (轮候冻结) of shares held by a controlling shareholder's concert party. It details the number of shares frozen, the proportion of shares affected, the reasons, and the potential risks to company control. The document is relatively short (2084 characters) and focuses on a specific event affecting shareholding and shareholder rights. It does not contain financial statements, audit information, or detailed management discussion. It is not a report but an announcement about a shareholder-related event, specifically about share freezing and risks to control. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about shareholding status and legal risks, not a financial report or voting result.
2024-09-05 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2024 年半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also includes information about shareholders, shareholding changes, and company operational updates. The length of the document is substantial (15,000 characters), and it contains actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.